Literature review shows thyroid hormones enhance treatment outcomes in patients with treatment-resistant depression, suggesting a potential augmentation strategy.
Key Points
Adjunctive triiodothyronine significantly enhances treatment response in treatment-resistant depression.
A randomized trial indicated 53% of patients on triiodothyronine had a significant improvement in depression scores after three weeks.
Thyroid hormone therapy may be more beneficial for women, as some studies suggest gender differences in treatment response.
Long-term efficacy of thyroid hormone therapy remains uncertain, highlighting the need for further research.